Compare PARK & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | GANX |
|---|---|---|
| Founded | 1972 | 2017 |
| Country | United States | United States |
| Employees | 1212 | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.4M | 76.4M |
| IPO Year | N/A | 2021 |
| Metric | PARK | GANX |
|---|---|---|
| Price | $20.95 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 33.1K | ★ 700.0K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $6.17 | N/A |
| P/E Ratio | $6.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.29 | $1.41 |
| 52 Week High | $22.68 | $4.34 |
| Indicator | PARK | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 49.09 |
| Support Level | $17.27 | $1.66 |
| Resistance Level | $21.65 | $2.12 |
| Average True Range (ATR) | 1.42 | 0.14 |
| MACD | 0.27 | 0.01 |
| Stochastic Oscillator | 69.15 | 24.11 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.